ATRS - Antares Pharma, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.1200
-0.1900 (-5.74%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.3100
Open3.2900
Bid3.0600 x 3000
Ask3.6900 x 4000
Day's Range3.1100 - 3.3400
52 Week Range1.9900 - 3.9600
Volume1,187,936
Avg. Volume981,277
Market Cap500.86M
Beta (3Y Monthly)0.98
PE Ratio (TTM)N/A
EPS (TTM)-0.0410
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.15
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents9 days ago

    Edited Transcript of ATRS earnings conference call or presentation 28-Feb-19 1:30pm GMT

    Q4 2018 Antares Pharma Inc Earnings Call

  • GuruFocus.com12 days ago

    Antares Pharma Inc (ATRS) Files 10-K for the Fiscal Year Ended on December 31, 2018

    Antares Pharma Inc is a specialty pharmaceutical company. Antares Pharma Inc had annual average EBITDA growth of 5.50% over the past five years. Warning! GuruFocus has detected 4 Warning Signs with ATRS.

  • AMAG's Stock Down as Pregnancy Drug Fails in PROLONG Study
    Zacks13 days ago

    AMAG's Stock Down as Pregnancy Drug Fails in PROLONG Study

    Shares of AMAG (AMAG) decline almost 17% after the company's pregnancy drug, Makena fails in the post approval PROLONG study.

  • GlobeNewswire18 days ago

    Antares Pharma to Present at the Cowen and Company 39th Annual Healthcare Conference

    Antares Pharma, Inc. (ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Cowen and Company 39th Annual Healthcare Conference on Wednesday March 13, 2019 at 8:40 am Eastern Time. Antares Pharma, Inc. is a combination drug device company focused on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery auto injector technology.  The Company has a portfolio of proprietary and partnered commercial products with several product candidates in advanced stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc. and Pfizer Inc. (Pfizer).  Antares Pharma’s proprietary products include XYOSTED™ (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.

  • GlobeNewswire20 days ago

    Antares Pharma Appoints Dr. Karen Smith to Board of Directors and Announces Retirement of Dr. Jacques Gonella

    EWING, N.J., March 04, 2019 -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced the appointment of Dr. Karen Smith to the Company’s Board of Directors, filling the seat.

  • Antares Pharma Inc (ATRS) Q4 2018 Earnings Conference Call Transcript
    Motley Fool24 days ago

    Antares Pharma Inc (ATRS) Q4 2018 Earnings Conference Call Transcript

    ATRS earnings call for the period ending December 31, 2018.

  • GlobeNewswire24 days ago

    Antares Pharma Reports Fourth Quarter and Full Year 2018 Operating and Financial Results

    Record Annual Revenue of $63.6 Million, a 17% Increase Over 2017 Revenue The Company Reaffirms 2019 Revenue Guidance of $95.0 to $105.0 Million EWING, N.J.,.

  • GlobeNewswire25 days ago

    Antares Pharma to Present at the Raymond James & Associates 40th Annual Institutional Investors Conference

    Antares Pharma, Inc. (ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Raymond James & Associates 40th Annual Institutional Investors Conference on Tuesday March 5, 2019 at 10:25 am Eastern Time. Antares Pharma, Inc. is a drug device combination products company focused on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery auto injector technology.  The Company has a portfolio of proprietary and partnered commercial products with several product candidates in advanced stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc. and Pfizer Inc. (Pfizer).  Antares Pharma’s proprietary products include XYOSTED™ (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.

  • GlobeNewswire27 days ago

    Antares Pharma to Report Fourth Quarter and Full Year 2018 Financial and Operating Results

    Antares Pharma, Inc. (ATRS) today announced it will release its fourth quarter and full year 2018 financial results and recent operating progress before the market opens on Thursday, February 28, 2019.  Management will host a webcast and conference call at 8:30 a.m. ET (Eastern Time) on February 28, 2019 to discuss the results.

  • Antares Pharma, Inc. (NASDAQ:ATRS): Time For A Financial Health Check
    Simply Wall St.2 months ago

    Antares Pharma, Inc. (NASDAQ:ATRS): Time For A Financial Health Check

    While small-cap stocks, such as Antares Pharma, Inc. (NASDAQ:ATRS) with its market cap of US$484m, are popular for their explosive growth, investors should also be aware of their balance sheet Read More...

  • Simply Wall St.3 months ago

    What Kind Of Shareholder Appears On The Antares Pharma, Inc.’s (NASDAQ:ATRS) Shareholder Register?

    If you want to know who really controls Antares Pharma, Inc. (NASDAQ:ATRS), then you'll have to look at the makeup of its share registry. Institutions will often hold stock in Read More...

  • GlobeNewswire3 months ago

    Antares Pharma Announces the Appointment of Peter S. Greenleaf to Company’s Board of Directors

    Antares Pharma, Inc. (ATRS) today announced the appointment of Peter S. Greenleaf to the Company’s Board of Directors.  Mr. Greenleaf has over 20 years of biopharmaceutical experience, and currently serves as the Chief Executive Officer of Cerecor Inc. (CERC), a biopharmaceutical company focused on neurological and pediatric disorders.  He is also Chairman of the Board at BioDelivery Sciences (BDSI), a specialty pharmaceutical company focused on pain management and addiction medicine.

  • Zacks Small Cap Research3 months ago

    ATRS: Xyosted & Epi Pen Available for Sale

    The last week of November was a good one for Antares Pharma, Inc. (ATRS) with both Epi Pen and Xyosted now commercially available. Teva Pharmaceuticals (TEVA) announced on November 27th that the recently approved AB-rated generic Epinephrine Pen is now available in the United States. For the remainder of 2018, only the Epi Pen 0.3 mg version will be available in limited quantities with additional supply of the 0.3 mg version and Epi Pen Jr (0.15 mg) to be available in 2019.

  • Should You Buy NanoString Technologies Inc (NSTG)?
    Insider Monkey3 months ago

    Should You Buy NanoString Technologies Inc (NSTG)?

    Before we spend many hours researching a company, we’d like to analyze what insiders, hedge funds and billionaire investors think of the stock first. We would like to do so because the elite investors’ consensus returns have been exceptional. In the following paragraphs, we find out what the billionaire investors and hedge funds think of […]

  • Is Noodles & Co (NDLS) A Good Stock To Buy?
    Insider Monkey4 months ago

    Is Noodles & Co (NDLS) A Good Stock To Buy?

    The 700+ hedge funds and money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the second quarter, which unveil their equity positions as of September 30. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund positions. Our extensive review […]

  • GlobeNewswire4 months ago

    Antares Pharma Announces the Commercial Availability of XYOSTED™ (Testosterone Enanthate) Injection — A New Treatment for Adult Men Diagnosed With Testosterone Deficiency

    Antares Pharma, Inc. (ATRS) today announced the availability of XYOSTED™ (testosterone enanthate) injection. XYOSTED™ is the only FDA approved subcutaneous testosterone product for once-weekly, at-home self-administration with an easy-to-use, single dose, disposable QuickShot® auto injector.  XYOSTED™ has been approved in three dosage strengths, 50 mg, 75 mg and 100 mg and is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone (see Indications and Usage below).  XYOSTED™ was approved by the U.S. Food and Drug Administration (“FDA”) on September 28, 2018.

  • Teva (TEVA) Launches First Generic Version of Mylan's EpiPen
    Zacks4 months ago

    Teva (TEVA) Launches First Generic Version of Mylan's EpiPen

    Teva (TEVA) launches the first approved generic version of Mylan's (MYL) popular EpiPen (epinephrine) auto-injector for severe allergy treatment in the United States.

  • Teva's generic EpiPen hits the market in limited doses
    American City Business Journals4 months ago

    Teva's generic EpiPen hits the market in limited doses

    Teva Pharmaceutical Industries on Tuesday released limited doses of its generic version of EpiPen Auto-Injector. Its generic EpiPen, developed in a partnership with New Jersey-based Antares Pharma, is carrying a price tag of $300. Mylan has come under criticism by government agencies and consumers because of price increases that have driven up the cost of the branded EpiPen injector from less than $100 to more than $600 during the past decade.

  • GlobeNewswire4 months ago

    Antares Pharma Partner Teva Announces Commercial Availability of Generic Epipen®

    Antares Pharma, Inc. (ATRS) (“Antares”) today announced that Teva Pharmaceutical Industries, Ltd.’s (“Teva”) generic EpiPen® is now commercially available in limited quantities. Teva’s generic EpiPen® was approved by the U.S. Food and Drug Administration (“FDA”) on August 16, 2018 and is indicated for emergency treatment of severe allergic reactions including those that are life threatening (anaphylaxis) in adults and certain pediatric patients. The product, which utilizes the Antares Pharma VIBEX® auto injector, has been approved as therapeutically equivalent and fully substitutable to the EpiPen® at the pharmacy.

  • Zacks Small Cap Research4 months ago

    ATRS: Xyosted Launch Before Year End

    Highlights for the quarter and quarter to date include FDA approval of Xyosted, FDA approval generic epinephrine pen and a new partnership with Pfizer (PFE). Strong sales of Makena at partner AMAG (AMAG) and optimism over a 2018 start to Xyosted sales were offset by weaker than expected sales for Otrexup and Sumatriptan. Antares Pharma, Inc. posted third quarter 2018 revenues of $17.9 million, representing 19% growth compared to prior year results of $15.1 million.

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of ATRS earnings conference call or presentation 6-Nov-18 1:30pm GMT

    Q3 2018 Antares Pharma Inc Earnings Call

  • GuruFocus.com4 months ago

    Healthcare Value Capital, LLC Buys Antares Pharma Inc, Sells Novelion Therapeutics Inc

    Woodcliff Lake, NJ, based Investment company Healthcare Value Capital, LLC buys Antares Pharma Inc, sells Novelion Therapeutics Inc during the 3-months ended 2018-09-30, according to the most recent filings ...

  • GlobeNewswire4 months ago

    Bragar Eagel & Squire, P.C. is Investigating Certain Officers and Directors of Antares Pharma, Inc. (ATRS) and Encourages ATRS Investors to Contact the Firm

    NEW YORK, Nov. 12, 2018 -- Bragar Eagel & Squire, P.C. is investigating potential claims against certain officers and directors of Antares Pharma, Inc. (NASDAQ: ATRS)..